TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Vitamin D Deficiency in Breastfed Infants
Brief Summary: Breastfed infants living in a northern location (41 degrees N) are at high risk of vitamin D deficiency during winter. This trial is designed to determine how much supplemental vitamin D breastfed infants need to receive in order to remain free of vitamin D deficiency


Options:
A: Arm Label: 200 IU/day Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 400 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 600 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 800 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day; Assigned to Arm(s): 200 IU/day Vitamin D, 400 IU/day Vitamin D, 600 IU/day Vitamin D, 800 IU/day Vitamin D
B: Arm Label: Vitamin D 150,000 units once; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Vitamin D 5000 units daily; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D 150,000 units once | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D 5000 units daily
C: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A, Group B, Group C, Group D
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Vitamin D Deficiency in Breastfed Infants
Brief Summary: Breastfed infants living in a northern location (41 degrees N) are at high risk of vitamin D deficiency during winter. This trial is designed to determine how much supplemental vitamin D breastfed infants need to receive in order to remain free of vitamin D deficiency


Options:
A: Arm Label: 200 IU/day Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 400 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 600 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 800 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day; Assigned to Arm(s): 200 IU/day Vitamin D, 400 IU/day Vitamin D, 600 IU/day Vitamin D, 800 IU/day Vitamin D
B: Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D3
C: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo, Vitamin D
D: Arm Label: High-dose vitamin D; Type: EXPERIMENTAL; Interventions: Drug: High-dose vitamin D 3 | Arm Label: Conventional-dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional-Dose Vitamin D 3 | Intervention Type: DRUG; Name: High-dose vitamin D 3; Assigned to Arm(s): High-dose vitamin D | Intervention Type: DRUG; Name: Conventional-Dose Vitamin D 3; Assigned to Arm(s): Conventional-dose vitamin D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intergenerational Transmission of Illness Behavior
Brief Summary: The purpose of this study is to evaluate the efficacy of a social learning and cognitive behavior therapy approach for treating children with Recurrent Abdominal Pain (RAP).


Options:
A: Arm Label: SLCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy & Social Learning | Arm Label: SLCBT-R; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy & Social Learning | Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education and Support | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy & Social Learning; Assigned to Arm(s): SLCBT, SLCBT-R | Intervention Type: BEHAVIORAL; Name: Education and Support; Assigned to Arm(s): ES
B: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
C: Arm Label: Coping Skills Training + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training, Drug: Amitriptyline | Arm Label: Headache Education + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Headache Education, Drug: Amitriptyline | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills Training + Amitriptyline | Intervention Type: BEHAVIORAL; Name: Headache Education; Assigned to Arm(s): Headache Education + Amitriptyline | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): Coping Skills Training + Amitriptyline, Headache Education + Amitriptyline
D: Arm Label: Wait List; Type: OTHER; Interventions: Behavioral: Wait list comparison group | Arm Label: 2 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 2 Family-based problem solving phone sessions | Arm Label: 4 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 4 Family-based problem solving phone intervention sessions | Intervention Type: BEHAVIORAL; Name: 2 Family-based problem solving phone sessions; Assigned to Arm(s): 2 phone sessions | Intervention Type: BEHAVIORAL; Name: 4 Family-based problem solving phone intervention sessions; Assigned to Arm(s): 4 phone sessions | Intervention Type: BEHAVIORAL; Name: Wait list comparison group; Assigned to Arm(s): Wait List

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intergenerational Transmission of Illness Behavior
Brief Summary: The purpose of this study is to evaluate the efficacy of a social learning and cognitive behavior therapy approach for treating children with Recurrent Abdominal Pain (RAP).


Options:
A: Arm Label: Active Comparator: Internet Resources Comparison (IRC); Type: EXPERIMENTAL; Interventions: Behavioral: Internet Resources Comparison (IRC) | Arm Label: I-InTERACT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT) | Arm Label: I-InTERACT Express; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express) | Intervention Type: BEHAVIORAL; Name: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT); Assigned to Arm(s): I-InTERACT | Intervention Type: BEHAVIORAL; Name: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express); Assigned to Arm(s): I-InTERACT Express | Intervention Type: BEHAVIORAL; Name: Internet Resources Comparison (IRC); Assigned to Arm(s): Active Comparator: Internet Resources Comparison (IRC)
B: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
C: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
D: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intergenerational Transmission of Illness Behavior
Brief Summary: The purpose of this study is to evaluate the efficacy of a social learning and cognitive behavior therapy approach for treating children with Recurrent Abdominal Pain (RAP).


Options:
A: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
B: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
C: Arm Label: Internet-based JIA Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Teens Taking Charge | Arm Label: Attention Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management | Intervention Type: BEHAVIORAL; Name: Teens Taking Charge; Assigned to Arm(s): Internet-based JIA Self-Management Program | Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): Attention Control Group
D: Arm Label: Coping Skills Training + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training, Drug: Amitriptyline | Arm Label: Headache Education + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Headache Education, Drug: Amitriptyline | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills Training + Amitriptyline | Intervention Type: BEHAVIORAL; Name: Headache Education; Assigned to Arm(s): Headache Education + Amitriptyline | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): Coping Skills Training + Amitriptyline, Headache Education + Amitriptyline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intergenerational Transmission of Illness Behavior
Brief Summary: The purpose of this study is to evaluate the efficacy of a social learning and cognitive behavior therapy approach for treating children with Recurrent Abdominal Pain (RAP).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Asthma Program | Intervention Type: BEHAVIORAL; Name: Telephone Asthma Program; Assigned to Arm(s): Intervention
B: Arm Label: CAPS; Type: EXPERIMENTAL; Interventions: Behavioral: Counselor-assisted problem solving (CAPS) | Arm Label: IRC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-resource comparison (IRC) | Intervention Type: BEHAVIORAL; Name: Counselor-assisted problem solving (CAPS); Assigned to Arm(s): CAPS | Intervention Type: BEHAVIORAL; Name: Internet-resource comparison (IRC); Assigned to Arm(s): IRC
C: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
D: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl vs Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes
Brief Summary: The purpose of this study is to determine the liver safety of pioglitazone, once daily (QD), versus glyburide taken with metformin and insulin.


Options:
A: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Glyburide QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glyburide | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Glyburide QD
B: Arm Label: Sitagliptin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin (MK0431) | Arm Label: Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glipizide | Intervention Type: DRUG; Name: sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: glipizide; Assigned to Arm(s): Glipizide
C: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 100 mg, Drug: Antihyperglycemic agent(s) | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300 mg, Drug: Antihyperglycemic agent(s) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antihyperglycemic agent(s), Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin 100 mg; Assigned to Arm(s): Canagliflozin 100 mg | Intervention Type: DRUG; Name: Canagliflozin 300 mg; Assigned to Arm(s): Canagliflozin 300 mg | Intervention Type: DRUG; Name: Antihyperglycemic agent(s); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Controlled Study of the Efficacy of NdYag for Hidradenitis Suppurativa
Brief Summary: * Determination of the short and long term efficacy of NdYag laser for treatment of Hidradenitis suppurativa, which is an inflamed, deeper follicular disorders.
* Determination of patient tolerance of discomfort associated with NdYag laser treatment for Hidradenitis suppurativa.
* Determination of the impact of this condition on quality of life and if there is any impact of therapy in the dermatology quality of life index.
* Evaluate the histopathologic changes of YAG therapy on affected skin

Second phase of study:

* Prospective, controlled clinical and histologic study of patients with Hurley Stage II HS disease.
* 19 patients of skin types II to VI with Hurley Stage II hidradenitis suppurativa lesions of the axilla and groin. This is a different set of patients than those treated in the first phase of the study above. This study primarily focuses on and further characterizes the histologic changes after laser treatment.


Options:
A: Arm Label: placebo controlled; Type: N/A; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): placebo controlled
B: Intervention Type: PROCEDURE; Name: Long-pulsed Nd:YAG laser 1064 nm; Assigned to Arm(s): N/A
C: Arm Label: infliximab; Type: EXPERIMENTAL; Interventions: Drug: infliximab, Drug: Placebo Comparator | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): infliximab | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo, infliximab
D: Arm Label: Adalimumab 40 mg qwk; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg qwk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer
Brief Summary: The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.


Options:
A: Arm Label: KU-0059436 (AZD2281) 100 mg BID; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Arm Label: KU-0059436 (AZD2281) 400 mg BID; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436 (AZD2281) 100 mg BID | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436 (AZD2281) 400 mg BID
B: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
C: Arm Label: Arm 1 (ceralasertib+olaparib); Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Ceralasertib | Arm Label: Arm 2 (olaparib monotherapy); Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Arm 3 (placebo); Type: EXPERIMENTAL; Interventions: Drug: Placebo to match olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib), Arm 2 (olaparib monotherapy) | Intervention Type: DRUG; Name: Ceralasertib; Assigned to Arm(s): Arm 1 (ceralasertib+olaparib) | Intervention Type: DRUG; Name: Placebo to match olaparib; Assigned to Arm(s): Arm 3 (placebo)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension
Brief Summary: Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human immunodeficiency virus (HIV) infection or collagen vascular disease).


Options:
A: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
B: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Iloprost, Drug: Bosentan | Arm Label: monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Iloprost; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Combination therapy, monotherapy
C: Intervention Type: DRUG; Name: Remodulin (treprostinil sodium); Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Ventavis (Iloprost, BAYQ6256) | Intervention Type: DRUG; Name: Ventavis (Iloprost, BAYQ6256); Assigned to Arm(s): Arm 1

Answer: C